Antibody drug conjugates: Potent weapons for the oncology arsenal

Chimica Oggi

Volumn 27, Issue 5, 2009, Pages 56-60

  Rohrer, Thomas ^a  

^a LONZA AG   (Switzerland)

Author keywords

ADC facility design; ADC linkers; ADC manufacturing; Antibody drug conjugates

Indexed keywords

EID: 72349100136     PISSN: 0392839X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. R.K. Jain, Tumour Physiology and Antibody Delivery", Front. Radiat. Ther. Oncol. 24, pp. 32-46 (1990).
2. G.M. Dubowchik, M.A. Walker, "Receptor-Mediated and Enzyme Dependent Targeting of Cytotoxic Anticancer Drugs", Pharmacol. Ther. 83, pp. 67-123 (1999).
3. K.W. Mosure, A.J. Henderson et al., "Disposition of Conjugate Bound and Free Doxorubicin in Tumour-Bearing Mice Following Administration of a BR96-Doxorubicin Immunocongate (BMS 182248)", Cancer Chemother. Pharmacol. 40, pp. 251-258 (1997).
4. R.J. Sanderson, M.A. Hering et al., "In Vivo Drug-linker Stability of an Anti-CD30 Dipeptide Linked Auristatin Immunoconjugate", Clin. Cancer Res. 11, pp. 843-852 (2005).
5. M.N Saleh et al., "Phase 1 Trial of The Anti-Lewis Y Drug Imunoconjugate BR96-Doxorubicin in Patients with Lewis Y-Expressing Epithelial Tumours", J. Clin. Oncol. 18, pp. 2282-2292 (2000).
6. E. Oflazoglu, K.M. Kissler et al., "Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves ant tumour activity in Hodgkin lymphoma", British Journal of Haematology 142, pp. 69-73 (2008).
7. A.M. Wu, P.D. Senter, "Arming Antibodies: Prospects and Challenges for Immunoconjugations", Nature Biotechnology 23, pp. 1137-1146 (2005).
8. F. Ruiz-Cabello, T. Cabrera et al., "Impaired Surface Antigen Presentation in Tumours: Implications for T Cell-Based Immunotherapy", Semin. Cancer Biolo. 12, pp. 15-24(2002).
9. C. Rader, D.A. Cheresh et al., "A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries", Proc. Natl. Acad. Sci. USA 95, pp. 8910-8915 (1998).
10. P.R. Hamann, L.M. Hinman et al., "A Calicheamicin Conjugate with a Fully Humanized Anti-MUC1 Antibody Shows Potent Antitumour Effects in Breast and Ovarian Tumour Xenografts", Bioconjug. Chem. 16, pp. 354-360(2005).
11. M. Beeran, H.A. Burris III et al., "A phase 1 study of trastuzumab-DM1 (T-DM1) a first in class HER2 antibody drug conjugate (ADC), in patients with advanced HER2+ breast cancer", J Clin Oncol. 26, (May 20 suppl; abstr 1028) (2008).
12. P.F. Bross, J. Beitz et al., "Approval Summary: Gemtuzumab Ozogamicin in Relapsed Acute Myeloid Leukemia", Clin Cancer Res. 7, pp. 1490-1496(2001).
13. R.M. Sharkey, D.M. Goldenberg, "Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates", CA Cancer J Clin. 56, pp. 226-243 (2006).
14. R.K. Oldham, R.O. Dillman, "Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress", J. Clin. Oncol. 26, pp. 1774-1777 (2008).
15. J. Chen, S. Jaracz et al., "Antibody-Cytotoxic Agent Conjugates for Cancer Therapy", Expert Opinion on Drug Delivery 2, pp. 873-890 (2005).
16. W.C. Widdison, S.D. Wilhelm, et al. "Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancel, J. Med. Chem. 49, pp. 4392-4408 (2006).